We are pleased to announce the appointment of Veit Bergendahl, PhD, as our Chief Operating Officer (COO) and member of the Executive Board. Effective April 1, 2026, he will be responsible for the operational areas of clinical and commercial cGMP manufacturing, engineering and technology, and production automation at Rentschler Biopharma.
Veit Bergendahl, PhD, brings more than 20 years of international experience in biopharmaceutical development, production, and CMC. Across Europe and the United States, he has built extensive experience at leading pharmaceutical and biotechnology companies, in contract development, and in research institutions.
Nikolaus F. Rentschler, PhD, Chairman of the Supervisory Board: “I am very pleased that Veit Bergendahl is taking on the role of Chief Operating Officer at the company enters a phase of further accelerated growth. With his strategic understanding of the biopharmaceutical value chain, his outstanding industry expertise, and many years of international experience in leadership roles, he will make a significant contribution to further strengthening our culture of reliability in a highly demanding market environment. His shared values and strong focus on partnership and sustainable development represent a significant asset for both our company and our clients.”
Uwe Buecheler, PhD, Interim CEO: “With Veit Bergendahl, whom I hold in the highest regard, we are gaining a highly experienced international leader who will strengthen our operations with his deep expertise and a clear forward-looking perspective. His comprehensive understanding of the development, manufacturing, and scaling of complex biopharmaceutical products is combined with a strong client focus and the highest commitment to quality. I particularly value his ability to link operational excellence with entrepreneurial thinking, inspiring teams to work toward shared goals. I am convinced that he will further accelerate the positive direction we have taken, especially through his strengths in innovation and operational excellence.”
Veit Bergendahl, PhD, incoming COO: “I am very much looking forward to working with the Executive Board and the team at Rentschler Biopharma. As a family-owned company and leading CDMO, Rentschler Biopharma delivers tailor-made solutions for essential biopharmaceuticals and combines scientific innovation with a strong sense of responsibility toward patients worldwide. It is very important to me to further build on this strong foundation. I aim to support and strengthen the dedicated teams in Laupheim and Milford, further enhance the robustness and efficiency of processes, and leverage new advances in technology to further advance operational excellence and develop long-term client- partnerships based on the highest levels of quality and reliability.”
Read the press release here: https://lnkd.in/d3s7csqP